All lobbying filings
TODD STRATEGY GROUP
Lobbying for ASTRAZENECA PHARMACEUTICALS LP · ​Biopharmaceutical Company.
Filing
Registration amendment
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 14, 2025
Money reported
None
Registrations and no-activity reports carry no figure.
Client based in
Delaware
Lobbyists on this filing
5
-
PAUL EDATTEL New on this filingPreviously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
-
ERIC BERGREN New on this filingPreviously held: Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
-
DANIEL M TODD New on this filingPreviously held: Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
-
KATHERINE FLEMING COTTON New on this filingPreviously held: Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
-
TED LEHMAN New on this filingPreviously held: Chief of Staff, Senator Tillis; Senate Judiciary Committee-Counsel, then Chief Counsel for Nominations and Senior Counsel; Senate Judiciary Committee-Staff Assistant and Legislative Assistant
Lobbying activity
2
340B Program. Home Infusion for Part B Products. Medicare Reimbursement for New Technologies. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection.
340B Program. Home Infusion for Part B Products. Medicare Reimbursement for New Technologies. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection.